A clinical trial in the November issue of Nature Medicine shows that a new vaccine against tuberculosis can induce a long-lasting boost of immune responses in people who previously received the widely used vaccine bacille Calmette-Guérin (BCG).
In a trial of a candidate vaccine against tuberculosis, Helen McShane and her colleagues found that a modified vaccinia virus expressing antigen 85A of Mycobacterium tuberculosis induced immune responses in volunteers that had never been vaccinated. And people who received BCG 0.5-38 years before the new vaccine had substantially stronger responses than subjects that solely received BCG.
Boosting vaccinations with the modified vaccinia virus could offer a practical and efficient strategy for enhancing antituberculosis immunity in areas in which the disease is endemic.
Helen McShane (University of Oxford, UK)
Tel: + 44 1865 857 417, E-mail: firstname.lastname@example.org
Also available online.
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking